SeptRx has reported the first implants of Intrapocket PFO Occluder (IPO) at the CardioVascular Center at Sankt Katharinen Hospital, Frankfurt, under the prospective, multi-center, single-arm In-tunnel SeptRx European PFO Trial (InterSEPT) clinical trial.

SeptRx IPO is a platform for the percutaneous transcatheter closure of a heart defect known as patent foramen ovale (PFO).

Results of InterSEPT trial will be used to apply for CE mark.

SeptRx CEO Scott Russell said they expect that InterSEPT trial results will position them for initial commercialization efforts in Europe.